Related Experiment Video
Updated: Aug 31, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
[Hepatitis B and C: current therapy]
H R Bruch1, U Höhner, R Müller
1Medizinische Klinik, Gastroenterologie-Hepatologie, Krankenhaus Siegburg.
Abstract:
Treatment of acute viral hepatitis B is symptomatic, fulminant cases may require liver transplantation. In chronic hepatitis B interferon (IFN)-alpha will induce sustained response rates of 30-40%. Nucleoside analogues such as famciclovir or lamivudine appear to be promising for treatment in non-responders or cirrhotic and immunosuppressed patients. IFN-alpha may reduce the rate of chronic courses in acute hepatitis C infections. Chronic hepatitis C patients with elevated ALT activities, positive serum HCV RNA and portal or bridging fibrosis on biopsy are recommended for treatment with IFN-alpha. Sustained responses are observed in less than 20% of treated patients. Retreatment with IFN-alpha may be indicated in non-responders or in case of relapse. Combination therapy of IFN-alpha plus ribavirin may emerge as treatment of choice for patients with a relapse in the near future.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction

